| Active ingredient (INN) | Atazanavir Sulfate |
|---|---|
| Brand names | Reyataz |
| ATC level 5 | J05AE08 |
| ATC level 4 | J05AE |
| Therapeutic category |
| Auto-created by U.S. Food and Drug Administration — Drug Shortages scraper |
| Controlled substance | No |
|---|
| Marketing-authorisation holders | TEVA PHARMACEUTICALS USA, INC., Aurobindo Pharma Limited |
|---|
| Registrations on file | 4 |
|---|
| Patient information leaflet (PIL) | Not on file |
|---|
| Summary of product characteristics (SPC) | Not on file |
|---|
| Product | Strength | Form | Market | MA holder | Status |
|---|---|---|---|---|---|
| Atazanavir Sulfate | 150mg/1 | capsule | 🇺🇸 US | TEVA PHARMACEUTICALS USA, INC. | Active |
| Atazanavir Sulfate | 200mg/1 | capsule | 🇺🇸 US | TEVA PHARMACEUTICALS USA, INC. | Active |
| Atazanavir Sulfate | 300mg/1 | capsule | 🇺🇸 US | TEVA PHARMACEUTICALS USA, INC. | Active |
| Atazanavir Sulfate | 100mg/1 | capsule | 🇺🇸 US | Aurobindo Pharma Limited | Active |